99 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
, to the Commission’s satisfaction, with all requests of the Commission for additional or supplemental information, if any. No stop order suspending … with to the Representatives’ reasonable satisfaction; and all necessary regulatory or stock exchange approvals shall have been received.
(b) (i) At the Closing Date
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
to close on or about May 7, 2024, subject to market conditions and the satisfaction of customary closing conditions.
Piper Sandler, Guggenheim … and assumptions, including the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related
8-K
EX-10.1
2xot0 t0hve
30 Jan 24
Departure of Directors or Certain Officers
4:57pm
S-3ASR
EX-4.3
mo36q2s
2 Jan 24
Automatic shelf registration
4:06pm
8-K
EX-99.1
lfrqvdyi7mj0p 8sm
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.1
j6kndz7d1ic0jc6aocvf
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.1
bokvq0eq0fy
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.2
gdle8fovauvxck0
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
79uqps0yo7dbhd1k4lxx
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
ix3k0dg
29 Sep 23
Prospectus supplement for primary offering
4:51pm
S-3MEF
EX-5.1
0218 ds2i
27 Sep 23
Registration of additional securities for an S-3
9:32pm
424B5
e9s9v fy2f5l
27 Sep 23
Prospectus supplement for primary offering
5:26pm